Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paula Morena, de Souza Guimarães"'
Autor:
Gabriela Bastos Cabral, Cintia Mayumi Ahagon, Paula Morena de Souza Guimarães, Giselle Ibette Silva Lopez-Lopes, Igor Mohamed Hussein, Audrey Cilli, Ivy de Jesus Alves, Andréa Gobetti Coelho Bombonatte, Maria do Carmo Sampaio Tavares Timenetsky, Jaqueline Helena da Silva Santos, Katia Corrêa de Oliveira Santos, Fabiana Cristina Pereira dos Santos, Luís Fernando de Macedo Brígido
Publikováno v:
Journal of Virological Methods
Vaccination and the emergence of SARS-CoV-2 variants mark the second year of the pandemic. Variants have amino acid mutations at the spike region, a viral protein central in the understanding of COVID-19 pathogenesis and vaccine response. Variants ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4476a8ec31c5df78b20808bb36bf00
https://pubmed.ncbi.nlm.nih.gov/34915086
https://pubmed.ncbi.nlm.nih.gov/34915086
Autor:
Paula Morena de Souza, Guimarães, João Leandro de Paula, Ferreira, Luana Portes Ozório, Coelho, Jaqueline de Souza, Cavalcanti, Giselle Ibette Silva Lopez, Lopes, Elaine Monteiro, Matsuda, Flávia Jacqueline, Almeida, Valéria Correia, Almeida, Alexandre Ely, Campeas, Luiz Carlos Pereira, Junior, Luís Fernando de Macedo, Brígido, Ana Cláudia, Diaz
Publikováno v:
AIDS Research and Human Retroviruses. 31:1219-1224
Transmitted drug resistance mutations (TDRM) have been a constant threat to treatment efficacy. We evaluated TDRM in plasma RNA of 217 antiretroviral therapy-naive patients from sites in the São Paulo metropolitan area, collected from 2012 to 2014.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb8f58f07b201b782302db774e9558c
https://doi.org/10.1089/aid.2014.0354
https://doi.org/10.1089/aid.2014.0354
Autor:
Paula Morena de Souza Guimarães, Luís Fernando de Macedo Brígido, Jaqueline de Souza Cavalcanti, José E. Vidal, João Leandro de Paula Ferreira
Publikováno v:
Journal of Antimicrobial Chemotherapy. 70:926-929
Received 28 August 2014; returned 26 September 2014; revised 7 October 2014; accepted 9 October 2014Objectives:Dolutegraviris a second-generationintegrase strand transfer inhibitor (InSTI) thathas been recentlyapproved by the FDA to treat antiretrovi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254babb255edfbdfdfb5323e6c3e660e
https://doi.org/10.1093/jac/dku439
https://doi.org/10.1093/jac/dku439
Autor:
Jaqueline, de Souza Cavalcanti, Joao Leandro, de Paula Ferreira, Jose Ernesto, Vidal, Paula Morena, de Souza Guimarães, Denise Helena, Moreira, Luis Fernando, de Macedo Brigido, Valeria, Almeida
Publikováno v:
International Journal of Antimicrobial Agents. 43:287-291
Raltegravir (RAL) is the first licensed antiretroviral integrase inhibitor that may be used both for treatment-naïve human immunodeficiency virus type 1 (HIV-1) patients and for salvage therapy. The Brazilian public free access programme limits its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270c7f6b77800bc7fd83956dd070362f
https://doi.org/10.1016/j.ijantimicag.2013.10.020
https://doi.org/10.1016/j.ijantimicag.2013.10.020
Autor:
Luís Fernando de Macedo Brígido, Luana Portes Ozório Coelho, Jaqueline de Souza Cavalcanti, Gabriela Bastos Cabral, Paula Morena de Souza Guimarães, Rosangela Rodrigues, João Leandro de Paula Ferreira
Publikováno v:
Journal of Virological Methods. 179(2):325-329
Determination of human immunodeficiency virus tropism has contributed to the understanding of the pathogenesis of HIV and is necessary prior to the use of CCR5 antagonists. Replicate V3 sequences may generate different sequences and improve viral tro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0070f03bac3f90572e397367e121bef
Autor:
Gabriela Bastos Cabral, Luís Fernando de Macedo Brígido, João Leandro de Paula Ferreira, Luana Portes Ozório Coelho, Paula Morena de Souza Guimarães
Publikováno v:
AIDS research and human retroviruses. 30(7)
HIV-1 tropism determination is necessary prior to CCR5 antagonist use as antiretroviral therapy. Genotypic prediction of coreceptor use is a practical alternative to phenotypic tests. Cell DNA and plasma RNA-based prediction has shown discordance in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca4dd153cff355dd2c336a21a1b3c95f
https://pubmed.ncbi.nlm.nih.gov/24673579
https://pubmed.ncbi.nlm.nih.gov/24673579